Bridgewater Associates LP Makes New $259,000 Investment in Qiagen (NYSE:QGEN)

Bridgewater Associates LP purchased a new stake in shares of Qiagen (NYSE:QGEN) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 5,825 shares of the company’s stock, valued at approximately $259,000.

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. Sanctuary Advisors LLC raised its position in Qiagen by 24.8% in the third quarter. Sanctuary Advisors LLC now owns 19,506 shares of the company’s stock worth $834,000 after acquiring an additional 3,878 shares in the last quarter. JPMorgan Chase & Co. boosted its holdings in shares of Qiagen by 36.0% in the third quarter. JPMorgan Chase & Co. now owns 1,604,034 shares of the company’s stock worth $73,096,000 after buying an additional 424,937 shares during the period. Park Avenue Securities LLC increased its position in shares of Qiagen by 32.1% in the fourth quarter. Park Avenue Securities LLC now owns 8,908 shares of the company’s stock worth $397,000 after acquiring an additional 2,166 shares in the last quarter. GAMMA Investing LLC raised its holdings in shares of Qiagen by 170.1% during the fourth quarter. GAMMA Investing LLC now owns 1,518 shares of the company’s stock valued at $68,000 after acquiring an additional 956 shares during the period. Finally, Assenagon Asset Management S.A. lifted its position in shares of Qiagen by 34.7% in the 4th quarter. Assenagon Asset Management S.A. now owns 16,409 shares of the company’s stock valued at $731,000 after acquiring an additional 4,225 shares in the last quarter. Institutional investors own 70.00% of the company’s stock.

Analyst Ratings Changes

Several brokerages have issued reports on QGEN. Redburn Atlantic downgraded shares of Qiagen from a “buy” rating to a “neutral” rating in a research note on Friday, April 4th. Robert W. Baird upped their price target on Qiagen from $42.00 to $43.00 and gave the company a “neutral” rating in a research report on Monday. Baird R W cut Qiagen from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, February 19th. UBS Group reduced their price target on shares of Qiagen from $50.00 to $48.00 and set a “neutral” rating for the company in a research report on Friday, February 7th. Finally, Morgan Stanley reaffirmed an “equal weight” rating and set a $46.67 price objective (down from $48.61) on shares of Qiagen in a research report on Monday, January 6th. Eight research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $47.83.

Qiagen Stock Up 4.6 %

QGEN stock opened at $42.33 on Wednesday. The firm has a market cap of $9.41 billion, a PE ratio of 117.87, a PEG ratio of 2.39 and a beta of 0.62. Qiagen has a 1 year low of $37.63 and a 1 year high of $49.30. The company has a fifty day simple moving average of $39.80 and a 200 day simple moving average of $41.71. The company has a current ratio of 3.61, a quick ratio of 3.09 and a debt-to-equity ratio of 0.38.

Qiagen (NYSE:QGEN) last released its quarterly earnings results on Wednesday, February 5th. The company reported $0.61 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.60 by $0.01. Qiagen had a return on equity of 13.92% and a net margin of 4.23%. Sell-side analysts anticipate that Qiagen will post 2.26 EPS for the current fiscal year.

Qiagen Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.